Digitalized Differential Diagnosis Broadening in Emergency Rooms
DDX-BRO
Effects of Digitalized Differential Diagnosis Broadening Using a Computerized Diagnostic Decision Support Tool on Diagnostic Quality in Emergency Room Patients - a Multi-centre Cluster Randomized Cross-over Trial.
1 other identifier
interventional
1,218
1 country
4
Brief Summary
10 to 35% of patients admitted to an emergency department receive an incorrect diagnosis. Not surprisingly, given the wide variety of health conditions encountered in emergency medicine, physicians often do not consider, remember, or know all possible diagnoses that fit the patient's symptoms. Nowadays, computer software (CDDS) is able to support physicians with a list of possible diagnoses by matching entered patient data to a large database with diagnoses. However, it is still unclear how the use of such a CDDS actually affects the diagnostic quality and workflow in 'real world' ER routine care. Therefore, the aim of this cluster-randomized cross-over trial is to evaluate the consequences of CDDS usage on diagnostic quality, patient outcomes and diagnostic workflow within the ER. Four ER's will provide a CDDS to the diagnosing physicians for specific periods (randomly and alternatingly allocated) in which physicians will be asked to use it for all included study patients. Outcomes between periods with and without the CDDS will be compared. Primary outcome is a diagnostic quality risk score composed of unscheduled ER revisits, unexpected hospitalization (both within 14 days), unexpected intensive medical care unit admission if hospitalized and diagnostic discrepancy between the ER discharge diagnosis and the current diagnosis after 14 days. In total, 1'184 patients will be included.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2022
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 21, 2022
CompletedFirst Posted
Study publicly available on registry
April 26, 2022
CompletedStudy Start
First participant enrolled
June 9, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 13, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 13, 2023
CompletedJuly 21, 2023
July 1, 2023
1.1 years
March 21, 2022
July 20, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diagnostic quality risk score
Primary endpoint is a binary score indicating a diagnostic quality risk, composed of: * Death within 14 days after emergency room discharge (yes/no) * Unscheduled medical care (emergency room revisits, General Practitioner visits or hospitalization) within 14 days after emergency room discharge (yes/no) * Unexpected intensive care unit admission from ward within 24 hours when hospitalized (yes/no) * Diagnostic discrepancy between the emergency room discharge diagnosis and the current diagnosis 14 days after emergency room discharge (yes/no)
From emergency room discharge to 14 days after emergency room discharge
Secondary Outcomes (15)
Death within 14 days after Emergency Room discharge (yes/no)
From emergency room discharge to 14 days after emergency room discharge
Unexpected intensive care unit admission
Within 24 hours from emergency room transfer to hospital ward
Diagnostic discrepancy
From emergency room discharge to 14 days after emergency room discharge
Unscheduled medical care 72 hours, 7 days and 14 days
From emergency room discharge to 72 hours, 7 days and 14 days after emergency room discharge
Length of emergency room stay
Time from emergency room admission to emergency room discharge, up to 24 hours
- +10 more secondary outcomes
Study Arms (2)
Usual Care + CDDS usage
EXPERIMENTALPatients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual but with support of the CDDS.
Usual Care
NO INTERVENTIONPatients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual without support of the CDDS.
Interventions
Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
Eligibility Criteria
You may qualify if:
- Informed Consent signed by the subject
- Presentation to the ER with fever, abdominal pain, syncope or Non-specific complaint (NSC) as chief complaint
- Triaged as "not vitally threatened"
- The study subject is 18 years old or older.
You may not qualify if:
- Trauma as chief complaint
- Pregnancy
- Worsening of a known pre-existing condition or medical referral with a definite diagnosis
- Inability to follow the informed consent and investigation procedures
- Previous enrolment into the current investigation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Dept. of internal and emergency medicine, Spital Münsigen
Münsingen, Canton of Bern, 3110, Switzerland
Dept. of Internal and Emergency Medicine, Spital Tiefenau
Bern, 3004, Switzerland
Dept. of Emergency Medicine, Inselspital, University Hospital Bern
Bern, 3010, Switzerland
Dept. of Internal and Emergency Medicine, Buergerspital Solothurn
Solothurn, 3004, Switzerland
Related Publications (2)
Hautz WE, Marcin T, Hautz SC, Schauber SK, Krummrey G, Muller M, Sauter TC, Lambrigger C, Schwappach D, Nendaz M, Lindner G, Bosbach S, Griesshammer I, Schonberg P, Pluss E, Romann V, Ravioli S, Werthmuller N, Kolbener F, Exadaktylos AK, Singh H, Zwaan L. Diagnoses supported by a computerised diagnostic decision support system versus conventional diagnoses in emergency patients (DDX-BRO): a multicentre, multiple-period, double-blind, cluster-randomised, crossover superiority trial. Lancet Digit Health. 2025 Feb;7(2):e136-e144. doi: 10.1016/S2589-7500(24)00250-4.
PMID: 39890244DERIVEDMarcin T, Hautz SC, Singh H, Zwaan L, Schwappach D, Krummrey G, Schauber SK, Nendaz M, Exadaktylos AK, Muller M, Lambrigger C, Sauter TC, Lindner G, Bosbach S, Griesshammer I, Hautz WE. Effects of a computerised diagnostic decision support tool on diagnostic quality in emergency departments: study protocol of the DDx-BRO multicentre cluster randomised cross-over trial. BMJ Open. 2023 Mar 29;13(3):e072649. doi: 10.1136/bmjopen-2023-072649.
PMID: 36990482DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wolf Hautz, Prof. MD
Prof. MD
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 21, 2022
First Posted
April 26, 2022
Study Start
June 9, 2022
Primary Completion
July 13, 2023
Study Completion
July 13, 2023
Last Updated
July 21, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will share
Researchers who wish to use IPD for a nested study need to submit a proposal to the Sponsor-Investigator and request permission. A concept sheet describing the planned analyses must be approved by the sponsor-investigator and PIs of the participating sites. Nested studies might need separate ethics permission.